Published in Cancer Res on July 23, 2014
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell (2015) 2.94
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol (2015) 1.37
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet (2015) 1.24
Approaches of targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov (2015) 0.84
Rho GTPases: Anti- or pro-neoplastic targets? Oncogene (2016) 0.84
Targeting RAS-mutant cancers: is ERK the key? Trends Cancer (2015) 0.82
RAC1 and melanoma. Clin Ther (2014) 0.79
Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms. Small GTPases (2016) 0.77
3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. Genome Med (2017) 0.77
Deregulation of Rho GTPases in cancer. Small GTPases (2016) 0.76
RAC1 P29S regulates PD-L1 expression in melanoma. Pigment Cell Melanoma Res (2015) 0.76
Regulation of viability, differentiation and death of human melanoma cells carrying neural stem cell biomarkers: a possibility for neural trans-differentiation. Apoptosis (2015) 0.76
P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. Mol Carcinog (2017) 0.75
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol (2016) 0.75
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer. BMC Bioinformatics (2016) 0.75
The Rac GTPase in cancer: from old concepts to new paradigms. Cancer Res (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol (2005) 16.77
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J Biol Chem (1999) 5.80
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27
Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer (2013) 2.23
False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia (2003) 2.09
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 1.97
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell Signal (2011) 1.61
Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol (2013) 1.24
Transforming mutations of RAC guanosine triphosphatases in human cancers. Proc Natl Acad Sci U S A (2013) 1.07
RAC1P29S is a spontaneously activating cancer-associated GTPase. Proc Natl Acad Sci U S A (2013) 1.05
C-RAF mutations confer resistance to RAF inhibitors. Cancer Res (2013) 0.91
Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol (2012) 0.84